Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885118 | 0.80 | CA1 (0.55) | SMN1; SMN2CA1RAB9ACA12CA2 | |
| SCHEMBL667530 | 0.76 | CA1 (0.47) | SMN1; SMN2LMNAHTTCA1NPC1 | |
| SCHEMBL43034 | 0.71 | — | — | |
| SCHEMBL1446301 | 0.71 | — | — | |
| SCHEMBL381097 | 0.69 | CA1 (0.56) | SMN1; SMN2LMNAHTTCA1NPC1 | |
| SCHEMBL25927091 | 0.69 | LMNA (0.32) | SMN1; SMN2LMNAHTTCA1TSHR | |
| SCHEMBL7824851 | 0.69 | CA1 (0.41) | SMN1; SMN2LMNAHTTCA1NPC1 | |
| SCHEMBL4089072 | 0.69 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNAHTTCA1NPC1 | |
| SCHEMBL2880721 | 0.69 | CA1 (0.38) | SMN1; SMN2LMNAHTTCA1NPC1 | |
| SCHEMBL13226853 | 0.69 | CA1 (0.41) | SMN1; SMN2LMNAHTTCA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210880-B1 | Benzoxazinone derivatives | MSD KK (JP) | 2015-08-26 | — | — | EP | disclosed |
| EP-2419408-A1 | 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K | 2012-02-02 | — | — | US | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| WO-2010119984-A1 | 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-21 | — | — | WO | disclosed |
| EP-2210880-A1 | BENZOXAZINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-7727998-B2 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| EP-1553089-B1 | ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | BANYU PHARMA CO LTD (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1553089-A1 | ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1505063-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1221443-B1 | SUBSTITUTED IMIDAZOLIDINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| US-6699880-B1 | STIMULATE MUSCARINIC ACETYLCHOLINE RECEPTORS M4, ANALGESICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-20030236267-A1 | Benzimidazole derivatives | MSD K.K. (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| EP-1221443-A1 | SUBSTITUTED IMIDAZOLIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | SMN1; SMN2 1070/4885LMNA 4373/4885HTT 3202/4885 |
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | IDO1, TPH1, AHR | SMN1; SMN2 3554/4885LMNA 1992/4885HTT 88/4885 |
| US-20030236267-A1 | Benzimidazole derivatives | OPRL1, GPR119, NPBWR1 | SMN1; SMN2 2200/4885LMNA 2385/4885HTT 797/4885 |
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | SMN1; SMN2 1453/4885LMNA 4017/4885HTT 355/4885 |
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | SMN1; SMN2 1869/4885LMNA 1460/4885HTT 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.